



# Illumina Closes Solexa Acquisition

Jan 26, 2007

NEW YORK (GenomeWeb News) — Illumina today said it has closed its \$600 million [acquisition of Solexa](#).

"We are excited to join the two companies, creating the only company with genome-scale technology for genotyping, gene expression, and sequencing, the three cornerstones of modern genetic analysis," Illumina CEO Jay Flatley said in a statement.

"With Solexa's recent technical achievements we look forward to the rapid commercialization of our next-generation sequencing platform," he added.

In connection with the merger, Illumina has increased the size of its board from eight to 10 members, adding Blaine Bowman and Roy Whitfield, both of whom were Solexa directors.

Illumina will report its fourth quarter financial results on Feb. 1.

Filed Under [Clinical Sequencing](#) [Sequencing](#) [Microarrays & Multiplexing](#) [microarrays](#)

## We recommend

[Acquiring Solexa in \\$600M Stock Deal, Illumina Targets \\$2.25B Market for Combined Genotyping-Sequencing Platform](#)

GenomeWeb

[Illumina Passes Antitrust Hurdle to Acquire Solexa](#)

GenomeWeb

[Accounting Rules Block Illumina From Booking Revenue For at Least 13 Sequencers](#)

GenomeWeb

[Illumina Expects Solexa Buy to Help Drive Up to 70 Percent Revenue Growth in 2007](#)

GenomeWeb

[Illumina Picked Solexa After Mulling Internal Development, Other Next-Gen Shops](#)

GenomeWeb

[Illumina Bets \\$600M Solexa Buy Will Help Uncover SNPs; Could Have Dx Role, Too](#)

GenomeWeb

Columbia Exhibit 2055  
Illumina, Inc. v. The Trustees  
of Columbia University in the  
City of New York  
IPR2018-00291, 318, 322 & 385



# Illumina Closes Solexa Acquisition

Jan 26, 2007

NEW YORK (GenomeWeb News) — Illumina today said it has closed its \$600 million [acquisition of Solexa](#).

"We are excited to join the two companies, creating the only company with genome-scale technology for genotyping, gene expression, and sequencing, the three cornerstones of modern genetic analysis," Illumina CEO Jay Flatley said in a statement.

"With Solexa's recent technical achievements we look forward to the rapid commercialization of our next-generation sequencing platform," he added.

In connection with the merger, Illumina has increased the size of its board from eight to 10 members, adding Blaine Bowman and Roy Whitfield, both of whom were Solexa directors.

Illumina will report its fourth quarter financial results on Feb. 1.

Filed Under [Clinical Sequencing](#) [Sequencing](#) [Microarrays & Multiplexing](#) [microarrays](#)

## We recommend

[Acquiring Solexa in \\$600M Stock Deal, Illumina Targets \\$2.25B Market for Combined Genotyping-Sequencing Platform](#)

GenomeWeb

[Illumina Passes Antitrust Hurdle to Acquire Solexa](#)

GenomeWeb

[Accounting Rules Block Illumina From Booking Revenue For at Least 13 Sequencers](#)

GenomeWeb

[Illumina Expects Solexa Buy to Help Drive Up to 70 Percent Revenue Growth in 2007](#)

GenomeWeb

[Illumina Picked Solexa After Mulling Internal Development, Other Next-Gen Shops](#)

GenomeWeb

[Illumina Bets \\$600M Solexa Buy Will Help Uncover SNPs; Could Have Dx Role, Too](#)

GenomeWeb

---

Powered by

